Your new experience awaits. Try the new design now and help us make it even better

OPINION article

Front. Neurol., 01 August 2025

Sec. Stroke

Volume 16 - 2025 | https://doi.org/10.3389/fneur.2025.1643988

SyNC as a cause of stroke: refining and expanding the concept and the name

  • Los Angeles Medical Center, University of California, Los Angeles, Los Angeles, CA, United States

Introduction

Recently, artery-to-artery embolism from a mild (1–49%) internal carotid artery atherosclerotic stenosis has been recognized as a common cause of ischemic stroke in patients whose events are otherwise cryptogenic (1, 2). The numbers tell the tale. In cryptogenic stroke patients, mildly stenosing plaques are present more often in the internal carotid artery that is ipsilateral, rather than contralateral, to the index infarct (3, 4). Similarly, in cryptogenic stroke patients, mildly stenosing plaques are present more often in the ipsilateral internal carotid artery than in patients with known cause stroke. In a recent meta-analysis of 16 studies enrolling 1,406 cryptogenic ischemic stroke patients, mildly stenosing internal carotid plaques with high risk features (intraplaque hemorrhage, thickness ≥3 mm, ulceration, or hypodensity) were present in 31% of ipsilateral compared with 14% of contralateral internal carotid arteries (5). Applying Bayes theorem to these contrasting rates indicates that artery-to-artery embolism from arising from mildly stenosing internal carotid stenosis is the cause of about 20% of otherwise cryptogenic anterior circulation ischemic strokes and about 4% of all ischemic strokes (6, 7).

To denote this important pathophysiologic entity, two acronyms have been advanced: SYmptomatic Non-stenosing Carotid (SyNC) disease and non-obstructive carotid atherosclerosis (NOCA), with SyNC far more widely adopted (8, 9). We will discuss these liabilities in relation to SyNC though they are equally applicable to NOCA.

Limitations of the current appellation

The SyNC acronym incorrectly characterizes the vessel lesion as non-stenosing. The degrees of artery steno-occlusion due to atherosclerosis encompasses five broad ranges: (1) complete occlusion (100%), (2) severe stenosis (70–99%), moderately severe stenosis (50–69%), mild stenosis (1–49%), and non-stenosing (0%) (10). The 0%, non-stenosing category exists because atherosclerosis can often induce expansive vessel remodeling so that the lumen is fully preserved despite the presence of atherosclerosis (11, 12). The term “non-stenosing” in the SyNC acronym therefore formally indicates that atherosclerotic lesions that produce 0% vessel stenosis are the stroke cause. But studies of this entity have overwhelmingly used 1–49% stenosis, not 0% stenosis. as a defining feature of the culprit plaque. Accordingly, the causal lesion is best denominated as “mildly stenosing” rather than “non-stenosing.”

Another limitation is that the SyNC acronym unduly confines this pathophysiologic entity to the internal carotid artery. Atherosclerosis arises at many additional sites in the aorto-cervico-cerebral tree including the thoracic aorta, common carotid artery origin, vertebral artery origin, intracranial vertebral artery, basilar artery, posterior cerebral artery, anterior cerebral artery, and middle cerebral artery (13) Atherosclerotic lesions provoking thrombosis and artery-to-artery embolism occur at each of these locations. Consequently, the vascular lesion location for this entity is best denominated much more broadly than simply “carotid.”

There are two potential approaches to correcting the infelicities of the current word components of the SyNC acronym: (1) change the words and the acronym; or (2) change the words but select new ones that permit retention of the current acronym. We have considered a variety of new, more accurate acronyms, including: MInimally Stenotic Symptomatic Atherosclerotic Plaque (MISSAP), Minimally Obstructive Atherosclerotic Plaque (MOAP), and Large Artery Atherosclerosis—Minimally Stenosing (LAA-MS). However, the SyNC rubric is now so well-established in the literature that wide uptake of a new acronym is unlikely. Accordingly, we propose a change in its component words, to: SYmptomatic, Non-severe, Cervicocerebral (SyNC) disease. “Non-severe encompasses the full range of causative stenoses from 0 to 49% rather than only the 0% captured by “non-stenosing.” “Cervicocerebral” captures the great preponderance of vessel sites at which this entity appears, rather than the limited coverage of “carotid.” The term cervicocerebral does have the drawback of not encompassing salient thoracic vascular sites—the aorta and the common carotid and vertebral artery origins. However, adding “thoraco” to “cervicocerebral” yields an unwieldy term difficult to remember. Since specification of the arterial location of the causative plaque in individual patients is desirable, we suggest appending a location letter or letters to the acronym to convey this information: e.g., SyNC-C (Symptomatic Non-Severe Cervicocerebral Plaque—Carotid), SyNC-V (Symptomatic Non-Severe Cervicocerebral Plaque—Vertebral), and SyNC-M (Symptomatic Non-Severe Cervicocerebral Plaque—Middle Cerebral).

Discussion

In summary, specifying the location of the atherosclerotic plaque and changing the acronym from non-stenosing to non-severe allows accurate description of stroke etiology. Precision in cerebrovascular pathophysiologic diagnosis and localization is a hallmark of vascular neurology. Correction and scope expansion of the SyNC acronym will further this core value of neurovascular research and clinical care.

Author contributions

RI: Writing – original draft, Writing – review & editing. JS: Writing – original draft, Writing – review & editing.

Funding

The author(s) declare that no financial support was received for the research and/or publication of this article.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Gen AI was used in the creation of this manuscript.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Ospel JM, Kappelhof M, Ganesh A, Kallmes DF, Brinjikji W, Goyal M. Symptomatic non-stenotic carotid disease: current challenges and opportunities for diagnosis and treatment. J Neurointerv Surg. (2024) 16:418–24. doi: 10.1136/jnis-2022-020005

PubMed Abstract | Crossref Full Text | Google Scholar

2. Savastano L, Brinjikji W, Lutsep H, Chen H, Chaturvedi S. Symptomatic nonstenotic carotids: a topical review. Stroke. (2024) 55:2921–31. doi: 10.1161/STROKEAHA.123.035675

PubMed Abstract | Crossref Full Text | Google Scholar

3. Coutinho JM, Derkatch S, Potvin AR, Tomlinson G, Kiehl TR, Silver FL, et al. Nonstenotic carotid plaque on CT angiography in patients with cryptogenic stroke. Neurology. (2016) 87:665–72. doi: 10.1212/WNL.0000000000002978

PubMed Abstract | Crossref Full Text | Google Scholar

4. Oak S, Cucchiara BL, Thau L, Nguyen TN, Sathya A, Reyes-Esteves S, et al. Age alters prevalence of left atrial enlargement and nonstenotic carotid plaque in embolic stroke of undetermined source. Stroke. (2022) 53:2260–7. doi: 10.1161/STROKEAHA.121.037522

PubMed Abstract | Crossref Full Text | Google Scholar

5. Rapillo CM, Giuricin A, Sarti C, Nesi M, Marcheselli S, Lombardo I, et al. Prevalence of carotid plaques with high-risk features in embolic stroke of undetermined source: systematic review and meta-analysis. Int J Stroke. (2025) 20:636–45. doi: 10.1177/17474930251317321

PubMed Abstract | Crossref Full Text | Google Scholar

6. Marko M, Singh N, Ospel JM, Uchida K, Almekhlafi MA, Demchuk AM, et al. Symptomatic non-stenotic carotid disease in embolic stroke of undetermined source: analysis of the ESCAPE-NA1 trial. Clin Neuroradiol. (2024) 34:333–9. doi: 10.1007/s00062-023-01365-0

PubMed Abstract | Crossref Full Text | Google Scholar

7. Chaisinanunkul N, Saver J. Abstract TP296: how often is nonstenotic carotid plaque in cryptogenic stroke causal versus incidental? Stroke. (2025) 56(Suppl_1). doi: 10.1161/str.56.suppl_1.TP296

Crossref Full Text | Google Scholar

8. Goyal M, Singh N, Marko M, Hill MD, Menon BK, Demchuk A, et al. Embolic stroke of undetermined source and symptomatic nonstenotic carotid disease. Stroke. (2020) 51:1321–5. doi: 10.1161/STROKEAHA.119.028853

PubMed Abstract | Crossref Full Text | Google Scholar

9. Jaffre A, Guidolin B, Ruidavets JB, Nasr N, Larrue V. Non-obstructive carotid atherosclerosis and patent foramen ovale in young adults with cryptogenic stroke. Eur J Neurol. (2017) 24:663–6. doi: 10.1111/ene.13275

PubMed Abstract | Crossref Full Text | Google Scholar

10. Bonati LH, Kakkos S, Berkefeld J, de Borst GJ, Bulbulia R, Halliday A, et al. European Stroke Organisation guideline on endarterectomy and stenting for carotid artery stenosis. Eur Stroke J. (2021) 6:I–XLVII. doi: 10.1177/23969873211012121

PubMed Abstract | Crossref Full Text | Google Scholar

11. Pasterkamp G, Smits PC. Imaging of atherosclerosis. Remodelling of coronary arteries. J Cardiovasc Risk. (2002) 9:229–35. doi: 10.1177/174182670200900502

PubMed Abstract | Crossref Full Text | Google Scholar

12. Gong B, Pian Y, Yang Q, Zhang J. Expansive arterial remodeling and its risk factors in cerebral infarction: a retrospective study. Neurologist. (2024) 30:132–9. doi: 10.1097/NRL.0000000000000600

PubMed Abstract | Crossref Full Text | Google Scholar

13. Qureshi AI, Caplan LR. Intracranial atherosclerosis. Lancet. (2013) 383:984–98. doi: 10.1016/S0140-6736(13)61088-0

PubMed Abstract | Crossref Full Text | Google Scholar

Keywords: stroke, atherosclerosis, carotid artery, Large Artery Atherosclerosis, cervical carotid artery disease

Citation: Iordanova R and Saver JL (2025) SyNC as a cause of stroke: refining and expanding the concept and the name. Front. Neurol. 16:1643988. doi: 10.3389/fneur.2025.1643988

Received: 09 June 2025; Accepted: 17 July 2025;
Published: 01 August 2025.

Edited by:

Jean-Claude Baron, University of Cambridge, United Kingdom

Reviewed by:

Marialuisa Zedde, IRCCS Local Health Authority of Reggio Emilia, Italy

Copyright © 2025 Iordanova and Saver. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Radostina Iordanova, SW5hMzkyQGdtYWlsLmNvbQ==

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.